Free Trial
NASDAQ:AEON

AEON Biopharma Q1 2024 Earnings Results & Report

AEON Biopharma logo
$0.23 -0.01 (-4.53%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$0.24 +0.00 (+2.16%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AEON Biopharma beat analyst earnings expectations in its Q1 2024 results, released May 14, 2024. The company reported EPS of -$20.16 versus the -$22.32 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2024
Report Date

AEON Biopharma EPS Results

Actual EPS
-$20.16
Consensus EPS
-$22.32
Beat/Miss
Beat by +$2.16
One Year Ago EPS
N/A

AEON Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

AEON Biopharma's next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules.

Conference Call Resources

AEON Biopharma Q1 2024 Earnings FAQ

AEON Biopharma (NASDAQ:AEON) reported earnings of -$20.16 per share for Q1 2024, beating the consensus estimate of -$22.32. The report was announced on Tuesday, May 14, 2024.

AEON Biopharma's next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for AEON Biopharma on the company's earnings history page.

AEON Biopharma Earnings Headlines

Zacks Research Forecasts AEON Biopharma Q3 Earnings
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
See More AEON Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AEON Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AEON Biopharma and other key companies, straight to your email.

About AEON Biopharma

AEON Biopharma (NASDAQ:AEON) is a clinical-stage biopharmaceutical company focused on developing therapeutic applications of botulinum toxin. Unlike companies that primarily target aesthetic uses, AEON is developing treatments for neurological and other medical conditions in which botulinum toxin may provide therapeutic benefits.

The company’s lead product candidate is ABP-450, an investigational botulinum neurotoxin type A complex licensed from Daewoong Pharmaceutical. AEON has evaluated ABP-450 in clinical programs targeting conditions including chronic migraine and cervical dystonia, and its broader development strategy may encompass additional therapeutic indications. ABP-450 has not received regulatory approval for these uses.

AEON Biopharma became a publicly traded company through a business combination with Priveterra Acquisition Corp. in 2023 and is headquartered in Irvine, California. The company’s programs are intended for markets in the United States and other international jurisdictions, subject to clinical results and regulatory approvals. Marc Forth serves as the company’s president and chief executive officer.

View AEON Biopharma Profile